Get the Stockscreener App
1.96
5.38%
0.10
After Hours:
1.97
0.01
+0.51%
Context Therapeutics Inc stock is traded at $1.96, with a volume of 144.10K.
It is up +5.38% in the last 24 hours and down -20.33% over the past month.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
See More
Previous Close:
$1.86
Open:
$1.85
24h Volume:
144.10K
Relative Volume:
0.96
Market Cap:
$148.50M
Revenue:
-
Net Income/Loss:
$-23.96M
P/E Ratio:
-1.6752
EPS:
-1.17
Net Cash Flow:
$-21.05M
1W Performance:
-5.77%
1M Performance:
-20.33%
6M Performance:
+42.03%
1Y Performance:
+29.80%
1-Day Range:
$1.85
$2.01
1-Week Range:
$1.73
$2.1925
52-Week Range:
$0.77
$2.75
Context Therapeutics Inc Stock (CNTX) Company Profile
Name
Context Therapeutics Inc
Sector
Industry
Phone
267-225-7416
Address
2001 MARKET STREET, PHILADELPHIA
Context Therapeutics Inc Stock (CNTX) Latest News
Ratios Reveal: Breaking Down Context Therapeutics Inc (CNTX)’s Financial Health - The Dwinnex
Driehaus Capital Management LLC Purchases Shares of 2,258,065 Context Therapeutics Inc. (NASDAQ:CNTX) - MarketBeat
Blue Owl Capital Holdings LP Takes $10.35 Million Position in Context Therapeutics Inc. (NASDAQ:CNTX) - MarketBeat
Century Therapeutics Announces Strategic Leadership Appointments - MyChesCo
Q3 2024 EPS Estimates for Context Therapeutics Inc. Reduced by HC Wainwright (NASDAQ:CNTX) - MarketBeat
BioAtla and Context Therapeutics Forge Strategic Agreement for Cancer Treatment Development - MSN
BioAtla and Context Therapeutics Forge Strategic Agreement for Cancer Treatment Development - MyChesCo
Affinity Asset Advisors LLC Makes New Investment in Tectonic Therapeutic (NASDAQ:TECX) - Defense World
Affinity Asset Advisors LLC Has $3.25 Million Stock Position in Context Therapeutics Inc. (NASDAQ:CNTX) - MarketBeat
Great Point Partners LLC Purchases Shares of 7,419,355 Context Therapeutics Inc. (NASDAQ:CNTX) - MarketBeat
Ally Bridge Group NY LLC Grows Stock Holdings in Context Therapeutics Inc. (NASDAQ:CNTX) - MarketBeat
Context Therapeutics’ (CNTX) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
BioAtla licenses cancer drug candidate to Context Therapeutics By Investing.com - Investing.com Canada
BioAtla licenses cancer drug candidate to Context Therapeutics - Investing.com
Ventyx deal a sign of Sanofi’s growing interest neuro-immunology? - BioCentury
Equities Research Analysts’ Updated EPS Estimates for September 23rd (AFRM, BITF, CAPR, CNTX, HPE, HSCS, JNPR, LUG, MNO, MNSO) - Defense World
Context Therapeutics (NASDAQ:CNTX) Earns "Buy" Rating from HC Wainwright - MarketBeat
Context Therapeutics signs second multimillion-dollar licensing deal in 3 months - The Business Journals
What is Context Therapeutics Inc (CNTX) Stock Return on Shareholders’ Capital? - SETE News
BioAtla licenses cancer drug candidate to Context Therapeutics - Investing.com India
Context Therapeutics Acquires Rights to Innovate Cancer Antibodies - TipRanks
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody - GlobeNewswire
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody - StockTitan
Financial Metrics Check: Twist Bioscience Corp (TWST)’s Ratios for Trailing Twelve Months - The Dwinnex
Twist Bioscience (NASDAQ:TWST) Trading Down 3% - Defense World
Weave Communications Inc (WEAV) may enjoy gains as insiders got busy in the recent days - Knox Daily
ContextSDK bags $4M Seed for Edge AI in mobile app development - Tech.eu
Vienna-based ContextSDK gets €3.6 million to build the future of app engagement and retention - EU-Startups
Context Therapeutics doubles authorized shares - Investing.com
ContextSDK snaps $4M from Speedinvest and others to supercharge app conversations - Tech Funding News
Are Smart Investors Making the Right Decision? Twist Bioscience Corp (TWST) - SETE News
Examining the Potential Price Growth of Twist Bioscience Corp (TWST) - Knox Daily
Context Therapeutics' (CNTX) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
We Think Context Therapeutics (NASDAQ:CNTX) Can Afford To Drive Business Growth - Yahoo Finance
Carisma Therapeutics and Moderna Expand Partnership to Target Autoimmune Diseases - MyChesCo
21,993 Shares in Warner Music Group Corp. (NASDAQ:WMG) Bought by Jupiter Asset Management Ltd. - Defense World
Are Medical Stocks Lagging Context Therapeutics Inc. (CNTX) This Year? - MSN
Unpacking Q2 Earnings: ServiceNow (NYSE:NOW) In The Context Of Other Automation Software Stocks - Yahoo Finance
Unpacking Q4 Earnings: Brown-Forman (NYSE:BF.B) In The Context Of Other Beverages and Alcohol Stocks - Yahoo Finance
Are Medical Stocks Lagging Context Therapeutics Inc. (CNTX) This Year? - Yahoo Finance
Passage Bio Welcomes Tom Kassberg to Board, Aiming to Strengthen Strategic Vision - MyChesCo
Piper Sandler maintains Overweight rating on Context Therapeutics shares - Investing.com India
Testicular Cancer Drugs Market Forecast Report 2024-2030Focus on Reducing Treatment Toxicity Enhances - Daily Guardian Canada
Testicular Cancer Drugs Market Forecast Report 2024-2030 - GlobeNewswire
SFA Therapeutics Appoints Dr. Ananda Gubbi as Director of Biostatistics to Enhance Drug Development - MyChesCo
Unpacking Q2 Earnings: Coca-Cola (NYSE:KO) In The Context Of Other Beverages and Alcohol Stocks - Yahoo Finance
Unpacking Q2 Earnings: Conagra (NYSE:CAG) In The Context Of Other Shelf-Stable Food Stocks - Yahoo Finance
Context Therapeutics Strengthens Board with Key Appointments - MSN
United Therapeutics Corporation's (NASDAQ:UTHR) Stock's On An Uptrend: Are Strong Financials Guiding The Market? - Simply Wall St
Context Therapeutics Strengthens Board with Key Appointments - MyChesCo
Unpacking Q2 Earnings: Alta (NYSE:ALTG) In The Context Of Other Specialty Equipment Distributors Stocks - Yahoo Finance
Context Therapeutics Inc Stock (CNTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):